

Figure S1. SB-431542 (TGF- β receptor kinase inhibitor) and PP2 (Src family kinase inhibitor) do not impact the (A) migration and (B) invasion of NUGC-3 cells. Scale bar, 300 μ m. ns, not significant; NT, non-treatment.




Figure S2. Migration and invasion of MKN74 gastric cancer cells are notably suppressed by the inhibitors SB-431542 and PP2. (A) PLT-induced enhanced migration and invasion of MKN74 cells was inhibited by SB-431542 (TGF- β receptor kinase inhibitor) and PP2 (Src family kinase inhibitor). Microscopic images of the (B) migration and (C) invasion assays with SB-431542 and PP2. Cell migration was regulated by both SB-431542 and PP2. Magnification, x100; scale bar, 300 μ m. ****P<0.0001 vs. PLT. NT, non-treatment; PLT, platelet.




Figure S3. Expression levels of MMP9 in gastric cancer cells. MMP9 expression in NUGC-3 cells was increased by PLTs and decreased by SB-431542 (TGF- β receptor kinase inhibitor) and PP2 (Src family kinase inhibitor). **** $P < 0.0001$ vs. PLT. NT, non-treatment; PLT, platelet.




Figure S4. Schematic diagram of the membrane receptor and intracellular molecules of platelet activation and the action point of PP2 in the present study. CLEC-2, C-type lectin-like receptor 2; GPVI, glycoprotein VI; IP3, inositol trisphosphate; P, phosphorylation.

